deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT04210037

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

A Multi-Center, Phase Ib/II Study of Combination Treatment of APG-1252 With Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Sponsor: Ascentage Pharma Group Inc.

Conditions Small Cell Lung Cancer
Interventions APG-1252 Paclitaxel
Updated 18 times since 2020 Last updated: Jul 8, 2022 Started: Aug 20, 2020 Primary completion: Aug 30, 2021 Completion: May 15, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decision

Other terminated trials from Ascentage Pharma Group Inc.

More terminations from Ascentage Pharma Group Inc.

Other Small Cell Lung Cancer trials with similar outcome

Browse all Small Cell Lung Cancer trials

Listed as NCT04210037, this PHASE1/PHASE2 trial focuses on Small Cell Lung Cancer and remains terminated or withdrawn. Sponsored by Ascentage Pharma Group Inc., it has been updated 18 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2020 – ~May 2020 · 4 months · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Dec 2021 · 6 months · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~Jun 2022 · 3 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Sep 2022 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Jun 2022 — Sep 2022 [monthly]

    Terminated PHASE1_PHASE2

    Status: Active Not Recruiting → Terminated

  5. Mar 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 13 earlier versions

  1. Dec 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Jun 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  3. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE1_PHASE2

  4. Mar 2021 — May 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1_PHASE2

  6. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  7. Oct 2020 — Dec 2020 [monthly]

    Recruiting PHASE1_PHASE2

  8. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE1_PHASE2

  9. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Jun 2020 — Jul 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  12. May 2020 — Jun 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  13. Jan 2020 — May 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ascentage Pharma Group Inc.
Data source: Ascentage Pharma Group Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations